AmVac and Taiwan National Health Research Institute Cooperate to Develop Nasal Spray Avian Flu Vaccine
AmVac AG (Zug, Switzerland) has formed a collaboration with the National Health Research Institutes in Taiwan to develop a nasal spray vaccine against the H5N1 avian influenza.
AmVac AG (Zug, Switzerland) has formed a collaboration with the National Health Research Institutes in Taiwan to develop a nasal spray vaccine against the H5N1 avian influenza.
The vaccine will use AmVac’s adjuvant, MALP-2, which is suitable for absorption through mucosal membranes.
Up to now, the development of a flu vaccine spray has been hampered by the lack of a safe adjuvant capable of enhancing strong mucosal immunity. AmVac has acquired exclusive rights to the adjuvant MALP-2 (Macrophage Activating Lipopeptide-2), developed by C. Guzman at the Helmholtz Center for Infection Research in Braunschweig, for all infectious diseases worldwide. This synthetic, well-tolerated class of adjuvants acts as a toll-like receptor agonist in activating cells of the immune system and thus at central sites in mediation of the immune response. Preliminary results in mice have revealed that the pandemic H5N1 flu vaccine combined with MALP-2 elicits flu-specific antibodies following intranasal immunization.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
